---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-23-000040"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:05:29.141086+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akebia extends loan maturity to March 2025, removes SOFR cap

## Summary
- Extended maturity of $35M Term Loans from Nov 2024 to March 31, 2025.
- Principal payments deferred until Oct 31, 2024, then monthly installments.
- Removed 3.35% SOFR cap; interest now SOFR+0.3%+7.5% (~13.15% at amendment).
- Prior capped rate was ~11.15%; removal increases borrowing cost.

## SEC filing metadata
- accession: 0001517022-23-000040
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000040/0001517022-23-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000040/akba-20231031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-23-000040
- JSON: https://secwatch.observer/filing/0001517022-23-000040.json
- Plain text: https://secwatch.observer/filing/0001517022-23-000040.txt

## Key facts
- Material Agreements
  Akebia Therapeutics, Inc. amended Fourth Amendment to Loan Agreement with BioPharma Credit PLC, BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP valued at $35.0 million (effective 2023-10-31).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: BioPharma Credit PLC, BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP
  - Value: $35.0 million
  - Effective: 2023-10-31
  source text: On October 31, 2023 (the “Fourth Amendment Effective Date”), Akebia Therapeutics, Inc. (the “Company”), BioPharma Credit PLC (the “Collateral Agent”), BPCR Limited Partnership (as a “Lender”) and BioPharma Credit Investments V (Master) LP (as a “Lender”) entered into the Fourth Amendment to Loan Agreement (the “Fourth Amendment”), which amends certain provisions of the Loan Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000040/0001517022-23-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.